LAWRENCE, Kan.–(BUSINESS WIRE)–#Endpoints11—Endpoints News, the biopharma industry’s source for breaking news, exclusive reporting and smart analysis, today unveiled this year’s Endpoints 11 winners — honoring 2025’s most exciting biotech startups.
The list this year includes startups representing the next generation of artificial intelligence-driven drug discovery, the rise of China’s biotech ecosystem, new approaches in cell and gene therapy, and ambitious new therapeutic modalities. All of the companies on 2025’s Endpoints 11 list are defined by major bets on breakthrough science that have the potential to change the trajectory of biotech.
“Our selection team has spent months vetting and debating our honorees. Even in the middle of a period of disruption and uncertainty in markets, policy and science, this year’s list of Endpoints 11 winners represents the best of the biotech industry,” said Endpoints News Executive Editor Drew Armstrong. “Congratulations to all of our honorees.”
The winners of the 2025 Endpoints 11 awards are:
- Averna Therapeutics: Harnessing jumping genes for a simple ‘all RNA’ gene therapy
- Candid Therapeutics: Ken Song and team move fast to build the next autoimmune powerhouse
- Chai Discovery: OpenAI-backed startup’s brainiac quartet aims to design drugs on the computer
- Dispatch Bio: Bringing ‘universality’ to cell therapies for solid tumors
- Judo Bio: Broadening the reach of RNA drugs
- Lila Sciences: Letting ‘scientific superintelligence’ run the lab
- Orbis Medicines: Using macrocycles to make a biologic-in-a-pill
- Sironax: A big swing in neurology as China biotech rises
- Stylus Medicine: Usurping viral proteins to bring CAR-T to the masses
- Third Arc: A small team with major league talent tackles some big disease targets
- Umoja: Breaking through the barriers that restrict CAR-T
Winners were honored last night at our gala in Boston, and full profiles of the companies were published this morning on endpoints.news. A look back at prior E11 winners and how they’ve fared is available here.
About Endpoints
Endpoints News is the biopharma industry’s trusted news authority. As part of the Financial Times’ FT Specialist group, Endpoints publishes daily newsletters, delivers award-winning reporting on its website, hosts industry-leading events and builds products connecting and informing sophisticated business audiences. For more information, visit endpoints.news.
Contacts
Drew Armstrong
Executive Editor
[email protected]
